Skip to main content
search

Immuno-oncology Simulator™

Revolutionizing immuno-oncology with predictive modeling

Meet a QSP expert

QSP model for immuno-oncology therapies

Certara’s Immuno-oncology (IO) Simulator is a cutting-edge QSP modeling platform designed to predict optimal drug combinations, dosing regimens, and biomarkers in virtual patients. By simulating the complex dynamics of the Cancer Immunity Cycle, the IO Simulator empowers researchers to make data-driven decisions for immuno-oncology therapies. This innovative tool integrates pre-clinical data to refine models and forecast clinical outcomes, enabling the development of personalized treatment strategies for specific indications and tumor phenotypes.

Simulates tumor, lymph, and blood compartments
Models interactions between tumor cells, T cells, dendritic cells, macrophages, NK cells, and cytokines
Supports drug modalities including mAb, bsAb, ADC, and small molecules

Features of the IO Simulator immuno-oncology modeling platform

The IO Simulator offers a mechanistic model of the Cancer Immunity Cycle, delivered through QSP Designer software. It facilitates modular development of a compound’s mechanism of action, calibrated with pre-clinical data, and integrates these models to predict clinical outcomes. Virtual trials conducted with the IO Simulator account for tumor heterogeneity, providing insights into optimal dosing and patient stratification biomarkers.

Modules of IO Simulator

  • Tumor, lymph, and blood compartments
  • Tumor cells
  • T cells
  • Dendritic cells
  • Macrophages
  • NK cells
  • Multiple cytokines

Drug modalities

  • mAb
  • bsAb
  • ADC
  • Small molecules

Meet the QSP expert

Andrzej Kierzek
1 / 1
Experts

Andrzej Kierzek

VP, QSP R&D

Driving innovation in QSP with 25+ years of expertise in molecular and systems biology, leading a team of 20+ scientists to build cutting-edge models and knowledgebases
linkedinConnect

Related resources

View all
1 / 2
Publication

Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm

Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno‐oncology (IO) the aim is to direct the patient’s...
Read more
2 / 2
White Paper

Optimize Immuno-oncology Drug Discovery and Development Using QSP

A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to better predict effective drug combinations, especially to more accurately correlate the physiological differences between preclinical models and human patients.
Read more

Explore our other QSP platform models

Certara offers Quantitative Systems Pharmacology (QSP) platform models across diverse therapeutic areas, enabling data-driven insights to accelerate drug development. Our tailored solutions integrate complex biological systems to support informed decision-making in research and clinical settings.

Certara’s Inflammatory Bowel Disease (IBD) QSP Platform Model is based on a mechanistic multi-state mathematical model to predict disease activity scores.

Read more

Certara’s Immunogenicity (IG) Simulator is a QSP immunogenicity prediction tool that predicts immunogenicity incidence and its impact on PK/PD.

Read more

Certara’s Vaccine Simulator uses Quantitative Systems Pharmacology (QSP) to determine optimal vaccine dosing strategies for patients.

Read more

Certara’s QSP models for neuroscience drug discovery offer mechanism-based models for Alzheimer’s, Parkinson’s, psychotic disorders, and more.

Read more

Speak to a QSP expert

Ask us how the IO Simulator can build confidence into your immuno-oncology therapies.

Predict optimal drug combinations and dosing regimens
Identify patient stratification biomarkers for personalized therapies
Simulate clinical outcomes with unparalleled precision